Vaxart Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$58.6M
Industry:Biotech
Founded:2004
Lead Investor(s):Care Capital
Press

Estimated Revenue & Financials

  • Vaxart's estimated revenue is currently $4.2M per year.
  • Vaxart received $18.4M in venture funding in January 2015.
  • Vaxart's estimated revenue per employee is $126030
  • Vaxart's total funding is $58.6M.

Employee Data

  • Vaxart has 33 Employees.
  • Vaxart grew their employee count by -15% last year.
  • Vaxart currently has 1 job openings.

Executive Contacts

NameTitle
Sean TuckerFounder/Chief Scientific Officer/Dir
John HarlandVice President Financial Planning and Administration
Keith GottliebAssociate Director, Clinical Immunology
Patti Orozco CroninSr. Director of Clinical Operations at Vaxart Inc.
Jaya NairDirector Of Manufacturing Operations
David IngamellsVice President of Manufacturing
David TaylorChief Medical Officer
Eric WenzelDirector, Clinical Development
Brant BiehnSenior VP Commercial Operations
Uday PatelVice President Regulatory Affairs

What Is Vaxart?

Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are prophylactic oral vaccines for seasonal influenza, RSV and norovirus, as well as a therapeutic vaccine for HPV types 16 and 18. Vaxart vaccines are convenient room temperature-stable tablets that are easy to administer, and that eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is listed on the NASDAQ exchange under ticker nymbol VXRT.

keywords:Biotechnology,Healthcare,Pharmaceuticals

33

Number of Employees

$4.2M

Revenue (est)

1

Current Jobs

-15%

Employee Growth %

$58.6M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.2M4310%$53M
Mission Bio
$10.7M7445%
Rigel Pharmaceu...
$42M2904%
ProTrials Resea...
$26.4M1823%
Trace Genomics
$5.9M4137%
Advanced Cell D...
$25.7M1788%
CellMax Life
$5.7M4011%$9M
Vaxart
$4.2M33-15%$58.6M
Full Spectrum A...
$6M425%
Calysta
$7.1M49-2%

Vaxart News

09/07/2019 - Vaxart to Present at the HC Wainwright 21st Annual Global ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant ...

09/08/2019 - Vaxart (NASDAQ:VXRT) Now Covered by Analysts at ...

Stock analysts at Brookline Capital Management assumed coverage on shares of Vaxart (NASDAQ:VXRT) in a research note issued on ...

09/07/2019 - Vaxart (NASDAQ:VXRT) Given a $2.00 Price Target at HC ...

Vaxart (NASDAQ:VXRT) has been given a $2.00 target price by HC Wainwright in a research note issued on Wednesday, August 21st, ...

Vaxart Funding

DateAmountRoundLead InvestorsReference
2007-11-16$3.3MAQuantum Technology Partners, Life Science AngelsArticle
2010-03-05$12.5MBCare Capital of Princeton NJArticle
2013-08-07$20.0MCArticle
2015-01-09$18.4MUndisclosedCare CapitalArticle

Vaxart Executive Hires

DateNameTitleReference
2014-05-09John M. HarlandCFOArticle
2016-02-10Samir SinghSVP corporate development and strategy.Article
2018-04-20Brant BiehnSVP Commercial OperationsArticle
2018-05-02David TaylorChief Medical OfficerArticle

Vaxart Acquisitions

DateCompany NameAmountNotesReference
2018-02-01Aviragen TherapeuticsArticle
2018-02-14Aviragen TherapeuticsArticle